← Leaderboards
Arvin Dar
Sloan-Kettering Inst Can Research
$9,617,218
Attributed
$13,503,681
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,503,681 · 5
By mechanism
R01$9,985,236 · 3
DP2$2,716,520 · 1
R56$801,925 · 1
Top collaborators
- Ross Leigh Cagan6 shared
- Ernesto Guccione6 shared
- Amaia Lujambio6 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- David B. Solit$21,393,031
- Xuejun Jiang$14,685,146
- Rona Yaeger$3,362,000
- Craig B Thompson$56,520,903
- Payam Gammage$948,006
Others in their field
Top investigators on “Phosphotransferases”
- David Heimbrook · Leidos Biomedical Research, Inc.$26,594,235
- Gary L. Johnson · National Jewish Health$21,727,284
- Peter Karl Sorger · Massachusetts Institute Of Technology$20,231,592
- Lewis C Cantley · Beth Israel Deaconess Medical Center$19,866,259
- Richard L Huganir · Johns Hopkins University$18,390,405
- Fulton T Crews · University Of North Carolina Chapel Hill$17,915,277
Research focus
PhosphotransferasesSmall MoleculeOncogenicMalignant NeoplasmsComplexInsightTumorSignal TransductionAnimalsStructureLeadCellsToxic EffectBiologyImmunotherapyPharmaceutical PreparationsCancer ModelIn VitroDesignAnalogMutantKras2 GeneMediatingSeries
Grant awards (24)
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer$655,407
R01 · FY2025 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$630,404
R01 · FY2025 · CA
Molecular Glues to Target RAS-MAPK Driven Cancers$479,518
R01 · FY2025 · CA · contact PI
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer$622,641
R01 · FY2024 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$598,885
R01 · FY2024 · CA
Molecular Glues to Target RAS-MAPK Driven Cancers$455,542
R01 · FY2024 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$617,796
R01 · FY2023 · CA
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer$504,213
R01 · FY2023 · CA · contact PI
Molecular Glues to Target RAS-MAPK Driven Cancers$356,264
R01 · FY2023 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$253,500
R01 · FY2023 · CA
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer$138,561
R01 · FY2023 · CA · contact PI
Molecular Glues to Target RAS-MAPK Driven Cancers$117,684
R01 · FY2023 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$617,796
R01 · FY2022 · CA
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer$604,219
R01 · FY2022 · CA · contact PI
Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSR$409,104
R01 · FY2022 · CA · contact PI
A Cytochrome P450 Therapeutic Space for Tauopathies$801,925
R56 · FY2021 · AG · contact PI
A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer$635,077
R01 · FY2021 · CA · contact PI
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS$631,336
R01 · FY2021 · CA · contact PI
Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSR$417,453
R01 · FY2021 · CA · contact PI
Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSR$417,453
R01 · FY2020 · CA · contact PI
Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSR$404,930
R01 · FY2019 · CA · contact PI
Targeting Oncogenic Ras-MAPK Signaling Complexes via the Scaffold KSR$417,453
R01 · FY2018 · CA · contact PI
Targeting Ras-Dependent Cancers with a Chemical Switch for an Inactive Kinase$174,020
DP2 · FY2017 · CA · contact PI
Targeting Ras-Dependent Cancers with a Chemical Switch for an Inactive Kinase$2,542,500
DP2 · FY2013 · CA · contact PI